Streetbeat News

MLTX

MoonLake Immunotherapeutics

https://www.moonlaketx.com

Industry

Biotechnology

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Open

51.98

Mkt cap

3.1B

Volume

401K

High

51.98

P/E Ratio

-38.45

52-wk high

64.98

Low

48.30

Div yield

N/A

52-wk low

37.55

MoonLake Immunotherapeutics is reportedly exploring a sale, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

July 14, 2023 | 7:40 pm

MoonLake Immunotherapeutics is reportedly exploring a sale, according to sources cited by Reuters. The company's stock symbol is MLTX.

Portfolio Pulse from Happy Mohamed

July 14, 2023 | 7:39 pm

The article lists potential short squeeze stocks to watch, including Asset Entities, Lightning eMotors, Bullfrog AI, Carvana, and others. High short interest and steep borrowing costs are common traits that could lead to a short squeeze. The top five short squeeze candidates are Asset Entities, Intuitive Machines, Toro Corp, MoonLake Immunotherapeutics, and Lightning eMotors.

Portfolio Pulse from Chris Katje

July 10, 2023 | 2:07 pm

Insiders at MoonLake Immunotherapeutics, The Simply Good Foods Company, and Walgreens Boots Alliance have recently made notable purchases of their companies' stocks. MoonLake's 10% owner Bihua Chen acquired 800,000 shares, costing around $40 million. Simply Good Foods' President and COO Geoff E Tanner bought 6,850 shares, costing around $250,758. Walgreens Boots Alliance's EVP, Pres. U.S. Healthcare John Driscoll purchased 5,172 shares, costing around $146,984.

Portfolio Pulse from Lisa Levin

July 06, 2023 | 12:58 pm

In Tuesday's after-market session, several healthcare stocks saw significant movement. Pasithea Therapeutics, GRI Bio, RVL Pharmaceuticals, MSP Recovery, Processa Pharma, and MoonLake saw gains ranging from 6.58% to 11.8%. On the other hand, Amneal Pharmaceuticals, Comera Life Sciences, Coeptis Therapeutics, SHL Telemedicine, LifeMD, and Vaccitech saw declines ranging from 6.76% to 14.8%.

Portfolio Pulse from Benzinga Insights

July 04, 2023 | 9:37 pm

MoonLake (NASDAQ:MLTX) has received mostly bullish ratings from analysts in the last quarter, with 7 out of 10 ratings being bullish. The average price target for the stock is $42.1, which is lower than its current price of $51.86, implying a potential downside. However, the average price target has increased by 26.81% over the past month.

Portfolio Pulse from Benzinga Insights

July 03, 2023 | 3:01 pm

The article lists the top five short squeeze candidates for the week, including Asset Entities, Intuitive Machines, Hub Cyber Security, MoonLake Immunotherapeutics, and Toro Corp. It also mentions other stocks to watch, such as Sientra Inc, Bullfrog AI Holdings, GuardForce AI, Torrid Holdings, and Genius Group.

Portfolio Pulse from Chris Katje

July 03, 2023 | 2:18 pm

Cantor Fitzgerald analyst Prakhar Agrawal maintains an Overweight rating on MoonLake (NASDAQ:MLTX) and raises the price target from $29 to $65.

Portfolio Pulse from richadhand@benzinga.com

July 03, 2023 | 1:18 pm

Moonlake Immunotherapeutics has upsized its underwritten public offering to 8 million shares at $50 per share, raising gross proceeds of $400 million.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 9:02 am

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Black Diamond Therapeutic (BDTX), Tivic Health Systems (TIVC), CalciMedica (CALC), Belite Bio (BLTE), MoonLake (MLTX), and Genelux (GNLX) saw their stocks rise, with BDTX leading the gainers with a 238.5% increase. On the other hand, Adicet Bio (ACET), Nkarta (NKTX), Terns Pharma (TERN), BioRestorative Therapies (BRTX), Viking Therapeutics (VKTX), and Benitec Biopharma (BNTC) experienced declines, with ACET leading the losers with a 53.6% decrease.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 5:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.